Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Acalabrutinib in ibrutinib-intolerant CLL patients: opening new doors

Kerry Rogers • 19 Jun 2019
ICML 2019
Chronic Lymphocytic Leukemia Leukemia Acalabrutinib

Kerry Rogers, MD, from the Ohio State University, Columbus, OH, discusses the Phase II study (NCT02717611) of acalabrutinib in ibrutinib-intolerant chronic lymphocytic leukemia (CLL) patients, and the potential implications of this data. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Kerry Rogers

2:20
The effect of ibrutinib dose-reduction on outcomes of patients with CLL/SLL: real-world evidence
Kerry Rogers • 8 Dec 2023
4:07
The long-term impact of early lenalidomide treatment on infections and secondary neoplasms in CLL
Kerry Rogers • 8 Dec 2023
5:34
Venetoclax added to ibrutinib in patients with CLL with molecular resistance to BTKi treatment
Kerry Rogers • 8 Dec 2023
1:18
Comorbidity and geriatric assessment tools in routine practice for CLL patients
Kerry Rogers • 7 Oct 2023

Related Videos

1:17
An ongoing Phase I/II study of sonrotoclax + zanubrutinib in patients with treatment-naive CLL/SLL
Piers Patten • 28 Apr 2024
1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
The content of VJHemOnc is intended for healthcare professionals